What You Should Know:
- The pharmaceutical and life sciences (PLS) sector is experiencing a resurgence in dealmaking activity, with a 20% increase in deal volume over the past year reported, according to PwC’s latest US Midyear Deals 2024 Outlook for Pharmaceutical and Life Sciences.
- M&A activity in the PLS sector is expected to remain strong throughout 2024 and potentially into 2025. Clarity on factors like US election outcomes and Federal Reserve interest rate decisions
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Sanofi and Biovac Join Forces to Manufacture Polio Vaccines in Africa
What You Should Know:
- Sanofi, a global healthcare leader, and Biovac, a prominent South African biopharmaceutical company, announced a landmark partnership. This collaboration aims to establish local manufacturing of inactivated polio vaccines (IPV) in Africa, serving the needs of over 40 African countries.
- Under this new partnership, Sanofi will continue producing the bulk IPV supply. Biovac, upon receiving marketing authorization, will oversee the final stages of formulation,
Read More
Aranscia and SignatureRX Partner to Optimize GLP-1 Medication Use
What You Should Know:
- Aranscia, a leader in personalized diagnostics, and Signature RX, a prominent pharmacy supplier, announced a collaborative effort to improve the effectiveness of GLP-1 medications.
- The multi-phase partnership focuses on developing personalized treatment plans and ensuring consistent access to these crucial medications.
GLP-1s: Beyond Type 2 Diabetes
Glucagon-like peptide-1 receptor agonists (GLP-1s) were initially developed for type 2 diabetes
Read More
Boston Scientific Acquires Silk Road Medical for $1.16B, Bolstering Stroke Prevention
What You Should Know:
- Boston Scientific Corporation (NYSE: BSX) announced a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK) for approximately $1.16 billion ($27.50 per share). Silk Road Medical is a leading innovator in minimally invasive stroke prevention technologies for patients with carotid artery disease.
- The acquisition strengthens Boston Scientific's position in the vascular medicine field, offering physicians a broader range of solutions for
Read More
Athos Therapeutics Taps Vultr Cloud GPU to Power AI Drug Discovery Engine
What You Should Know:
- Vultr, the world’s largest, privately-held cloud computing platform, today announced that Athos Therapeutics, Inc. (“Athos”), a clinical-stage biotechnology company, has chosen Vultr Cloud GPU to run its AI model training, tuning, and inference.
- Powered by NVIDIA HGX H100 systems and running on Dell
Read More
Mika Health, AstraZeneca, and Daiichi Sankyo Partner on UNITE Program
What You Should Know:
- Mika Health, a leading developer of digital therapeutics for cancer patients, announced a collaborative initiative called "UNITE" alongside pharmaceutical giants AstraZeneca and Daiichi Sankyo.
- The strategic initiative signifies a commitment to cross-industry collaboration to enhance the lives of cancer patients and is expected to pave the way for AI-powered solutions in other disease areas.
Mika Health: A Proven Digital Therapeutic Platform
Mika
Read More
Medidata Launches New AI Solution to Modernize the Data Experience in Clinical Trials
What You Should Know:
- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced the launch of Medidata Clinical Data Studio, a unified experience that unlocks the true power of clinical research data.
- This groundbreaking technology gives stakeholders greater control over the quality of data and the ability to deliver safer trials to patients
Read More
Closing the Cell Therapy Access Gap with Closed Manufacturing Systems
Cell and gene therapies have the potential to revolutionize medicine. These groundbreaking treatments use living cells to target and treat disease, and they will have a profound impact on the treatment of cancer, autoimmune diseases, and beyond. However, while scientific advancements in this field are accelerating quickly, manufacturing these treatments has remained costly and slow.
The access gap between patients eligible for cell therapy and those able to receive treatment is overwhelming.
Read More
Foresite Capital Closes $900M Fund Targeting Precision Medicine & Innovation
What You Should Know:
- Foresite Capital, a San Francisco, CA-based healthcare and life sciences investment firm, announced today the successful closing of its sixth fund with a significant $900M in capital commitments. This new fund fuels Foresite's mission to invest in groundbreaking technologies across the healthcare spectrum.
- Fund VI attracted a diverse group of limited partners, including university endowments, charitable foundations, medical institutions, pension funds,
Read More
AlidaBio Secures $7.5M to Optimize Epitranscriptomic Research
What You Should Know:
- Alida Biosciences (AlidaBio), an innovator in epigenomic research tools, proudly announces the successful completion of a $7.5 million Series A funding round. This funding, led by Genoa Ventures with participation from FusionX Ventures and Vertical Venture Partners, is complemented by two ongoing SBIR grants totaling $4 million from The National Human Genome Research Institute
Read More
